廣告
香港股市 已收市
  • 恒指

    16,541.42
    +148.58 (+0.91%)
     
  • 國指

    5,810.79
    +82.66 (+1.44%)
     
  • 上證綜指

    3,010.66
    +17.52 (+0.59%)
     
  • 道指

    39,760.08
    +477.75 (+1.22%)
     
  • 標普 500

    5,248.49
    +44.91 (+0.86%)
     
  • 納指

    16,399.52
    +83.82 (+0.51%)
     
  • Vix指數

    12.95
    +0.17 (+1.33%)
     
  • 富時100

    7,957.59
    +25.61 (+0.32%)
     
  • 紐約期油

    81.82
    +0.47 (+0.58%)
     
  • 金價

    2,216.60
    +3.90 (+0.18%)
     
  • 美元

    7.8233
    +0.0002 (+0.00%)
     
  • 人民幣

    0.9235
    +0.0003 (+0.03%)
     
  • 日圓

    0.0514
    -0.0001 (-0.12%)
     
  • 歐元

    8.4386
    -0.0306 (-0.36%)
     
  • Bitcoin

    70,653.34
    +1,137.41 (+1.64%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

Sana Biotechnology Outlines Pipeline Prioritization, Reduces Workforce

  • Sana Biotechnology Inc (NASDAQ: SANA) announced a portfolio prioritization expected to provide a cash runway into 2025.

  • The resulting changes include focusing its second HIP-modified allogeneic CAR T program on targeting CD22 for CD19 CAR T failures, halting further internal investment in its SC187 program (cardiomyocytes for heart failure), and stage-gating certain platform investments based upon clinical progress in humans.

  • The prioritization and restructuring reduced the company's headcount by approximately 15%.

  • Related: Sana Biotechnology Inks Two Licensing Pacts For Targets Against Hematological Malignancies.

  • Sana remains on track to file an IND this year for SC291 (HIP-modified, CD19-targeted allogeneic CAR T), with initial clinical data expected in 2023.

  • For SC263 and SG295, Sana expects to file an IND in 2023.

  • For SC451 (HIP-modified, stem-cell derived pancreatic islet cell therapy for patients with type 1 diabetes) and SC255 (HIP-modified, BCMA-targeted allogeneic CAR T) for multiple myeloma, the company will file an IND in 2024.

  • Price Action: SANA shares closed at $4.71 on Tuesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.